CLDN4, claudin 4, 1364

N. diseases: 164; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 Biomarker group BEFREE Claudin-4 staining was positive in 131/137 (95.6%) adenocarcinoma cases. 31390089 2019
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 Biomarker group BEFREE Immunocytochemical studies on PF cell blocks allow: (a) to distinguish mesothelioma from reactive mesothelial proliferations (e.g. loss of BAP1 nuclear expression, complemented by the demonstration of p16 deletion using fluorescence in situ hybridization, indicate mesothelioma); (b) to separate mesothelioma from adenocarcinoma (e.g. calretinin, CK 5/6, WT-1 and D2-40 are markers of mesothelioma, whereas CEA, EPCAM, TTF-1, napsin A, and claudin 4 are markers of carcinoma); and (c) to reveal tumor origin in pleural metastases of an unknown primary site (e.g. 30354850 2019
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 Biomarker group BEFREE CRLMs and PLMs also were strongly positive for claudin-4, while being virtually undetectable in HCC. 23385421 2013
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 AlteredExpression group BEFREE Claudin-4, encoding a protein for tight junction formation and function, is highly overexpressed in pancreatic ductal adenocarcinoma and is also associated with invasive adenocarcinomas arising in intraductal papillary mucinous neoplasms of the pancreas. 21102412 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 AlteredExpression group BEFREE Claudin-4 expression was significantly decreased in tumors with undifferentiated-type adenocarcinoma, advanced T stage, lymph node metastasis, and peritoneal metastasis. 19390931 2009
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 AlteredExpression group LHGDN Distinct claudin expression profile in histologic subtypes of lung cancer. 17418912 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 AlteredExpression group BEFREE The microarray experiment revealed CLDN3 and CLDN4 transcripts were significantly up-regulated by 5-fold or more in most subtypes of ovarian epithelial carcinomas while the immunohistochemical analyses indicated that each protein was expressed in 68 (81.0%) and 72 (85.7%) of 84 serous adenocarcinomas, respectively. 17647191 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.080 Biomarker group BEFREE Claudin 4 was significantly increased in both borderline-type and ovarian adenocarcinomas compared to benign tumours, whereas no changes were found for claudin 1 or 5. 16287068 2006